Frost & Sullivan

MARCH 22, 2024

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% growth from 2023 to 2024. What is driving transformation in the pharma industry? increase from 2022. However, the pharma/biopharma industry shows overall stagnant R&D activity.

Ecosystems 52

Ecosystems Biopharma Biotech Contract research organization 52

Frost & Sullivan

SEPTEMBER 19, 2023

San Antonio, TX — September 19, 2023 — Frost & Sullivan recently researched the life sciences quality management and compliance solutions and services industry and, based on its findings, recognizes Verista with the 2023 Global Customer Value Leadership Award.

Life science 52

Life science Biotech 52

Frost & Sullivan

FEBRUARY 15, 2024

Small- to mid-sized pharma/biotech players in APAC are rivaling Europe in clinical trials through multiple CRO partnerships in the region, tapping into a population-rich landscape.

Ecosystems 40

Ecosystems Contract research organization Biotech Utilities 40

LaVoie Health Science Blog

JANUARY 30, 2023

Here are the five key takeaways of the conference and what to expect as we come to the end the first month of the year: Biotech is Back: The COVID-19 pandemic caused a downturn for the biotech sector as whole, but JP Morgan Week showed a strong turnout, proving interest in both the science and investor sides of the industry.

Biotech 98

Biotech Biotechnology Finance Data partnerships 98

Jake Jorgovan

DECEMBER 11, 2024

For instance, in November 2023, the Centers for Medicare & Medicaid Services (CMS) finalized a 3.4% As of 2023, 70% of hospitals were in compliance with both parts of the Hospital Price Transparency Rule, up from 27% in 2021. billion in 2023 , is projected to reach $43.4

Legal 130

Legal Insurance Biotech Collaboration 130

Frost & Sullivan

FEBRUARY 6, 2023

Collaborations and R&D investment in advanced therapies – Bio-CDMOs like Piramal Pharma Limited can align themselves as co-development partners for antibody drug conjugates (ADCs), whereas emerging biotech like Regrow Biosciences continues to focus on the innovation and commercialization of cell therapies.

Life science 52

Life science Biotech Ecosystems Finance 52

Frost & Sullivan

MARCH 28, 2025

Download our full analysis on the top 6 growth opportunities in pharma and biotech. Between 2017 and 2023, the US RLT market saw over 550% growth in total venture capital deals. The post Pharma & Biotech in 2025: The Top 6 Growth Opportunities Shaping the Future appeared first on Frost & Sullivan. Want deeper insights?

Biotech 52

Biotech Biotechnology Strategic partnership Insurance 52

Frost & Sullivan

OCTOBER 11, 2024

San Antonio, TX — 14 th October 2024 — Frost & Sullivan recently conducted an in-depth analysis of the biotech contract research organization (CRO) industry and based on its findings, has awarded Novotech the 2024 Global Company of the Year Award.

Biotech 52

Biotech Contract research organization Strategic partnership Life science 52

Frost & Sullivan

MARCH 5, 2025

Investment Outlook: Biohybrid technologies will see strong adoption in biotech, environmental science, and smart wearables. Regional Insights: APAC: South Korean startups like PAENE Biotech are pioneering mitochondrial-targeted therapies. Leverage strategic partnerships in clean energy, biotech, and smart infrastructure.

Biotech 52

Biotech Energy Fintech Construction 52

Jake Jorgovan

JANUARY 31, 2025

In 2023, recruiters adding AI skills to their profiles increased by 14%, signaling growing adoption. The market will also see the rise of hyper-specialized search firms, using niche data analytics to identify top talent in emerging industries like clean tech, biotech, and AI.

Biotech 130

Biotech Collaboration Utilities Government 130

Frost & Sullivan

FEBRUARY 20, 2025

Investment Outlook: Expect biotech & pharma companies to increase R&D partnerships in nanoencapsulation and targeted drug delivery. Regional Insights : India: The DPDP Act (2023) is pushing companies to enhance identity security and Zero Trust models. Explore the latest innovations and strategies driving growth.

Biotech 52

Biotech Energy Banking Government 52

Frost & Sullivan

MARCH 28, 2025

Elabscience Biotechnology, Inc., Quanterix, Response Biomedical Corp., Tosoh Bioscience, Tulip Diagnostics Pvt. Notable Mergers & Acquisitions Roches acquisition of LumiraDxs POC business will enhance its POC capabilities and market presence.

Biotechnology 52

Biotechnology Biotech Ecosystems 52

Frost & Sullivan

JANUARY 23, 2025

The 43rd JP Morgan Healthcare Conference , held from January 1316, 2025, in San Francisco, brought together a vibrant ecosystem of global pharma stakeholders, innovative startups, emerging biotech companies, and investors.

Biotechnology 52

Biotechnology Mergers and acquisition activities Biotech Biopharma 52